TNIP3 and metabolic dysfunction-associated steatohepatitis: Focusing on research in cardiovascular metabolic diseases for several years, our previous studies have demonstrated that TNIP3 acts as a novel endogenous suppressor of nonalcoholic steatohepatitis by interrupting TAK1 activation [14].